Pacific Biosciences of California, Inc. (PACB)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore >= 3 before any bullish entry. Liquidity and blackout checks pass, and the chart has improved, but the hard fundamental override blocks a long setup.
Company overview
Pacific Biosciences of California, Inc. develops and manufactures genetic sequencing platforms, including the PacBio Sequencing Systems and SMRT cells, for research and diagnostic use. The company serves a global clientele, including research institutions and pharmaceutical firms, through direct sales and distribution partners. It was founded in 2000 and is headquartered in Menlo Park, California.
Fundamental
weakPACB's fundamentals are weak due to ongoing cash burn, high leverage, and dilution risk.
PACB’s gross margin has improved, but the company is still burning cash with large losses and a heavily debt-weighted capital structure. Liquidity helps near-term runway, yet weak distress metrics, dilution risk, and negative DCF outputs keep overall fundamentals weak.
Sentiment
fairMedia sentiment is neutral, with no significant catalysts or red flags identified.
Last ~14d media sentiment on PACB is neutral at aggregator tier (primary-tier coverage was empty), cooling from a mixed/slightly positive 30–90d backdrop driven by Q1 results and partnership/product headlines. No near-term actionable catalysts surfaced and retail sentiment is indeterminate (Reddit rate limits), while the legal scan found no cases and no regulator-confirmed investigation signals (investigation analyzer failed), so no red-flag cap applied.
Technical
goodShort-term technicals are positive, with PACB trading above key moving averages and showing bullish momentum.
The short-term tape has improved meaningfully. Using the latest available trading day, PACB is above SMA20 (1.43), SMA50 (1.45), EMA9 (1.41), EMA21 (1.40), and daily VWAP (1.57), which confirms a near-term bullish reversal off the May base. Momentum is constructive: RSI14 is 62.57, Williams %R is -22.35, MACD has crossed above its signal near the zero line (0.00 vs -0.01, histogram 0.02), and ADX14 at 38.24 shows strong trend intensity. Volume confirms the move, with 20-day average dollar volume at $8.70M and the last three sessions averaging about $9.69M, while recent up-day volume has exceeded the latest down-day volume. The clear blemish is that price remains below the SMA200 (1.69) and is now pushing into resistance from the 1.63-1.68 area, so the chart is stronger but not fully repaired on a longer-term basis.
You’re looking at 2026-06-25 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.